-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Indices, IPOs, and New Drug Approvals – Update July 6th 2012
1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M. The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >
#Partnering Wrap Up for BIO International Convention
A very big thank you to all the companies, sponsors, and attendees of the BIO Business Forum and Exhibitor Partnering. We’re very excited at the level of activity, feedback, and business getting done, right in the biotech hub of Boston. As you know, we scheduled over 25,000 meetings. Here are the official stats, as of this morning: Total Requests 127,635 Scheduled Meetings 25,291 Companies 2,900 Countries 58 What do those stats really mean? Here’s the Read More >
Phase III Assets in High Demand – Results from the Business Forum Meeting Activity
At the BIO International Convention in Boston today, we released our results from the Business Forum meeting activity. This analysis provides a real-time snapshot of what in-licensors from pharma and biotech are looking for here at the conference. The Business Forum hit over 25,000 scheduled One-on-One Partnering™ meetings on Monday afternoon. This is 18% more meetings than last year, and more than double the meetings held back in 2007, when we last held this event in Read More >
What’s the Buzz?
Meet Deuteria Pharmaceuticals, winner of the 2012 Buzz of BIO competition. What is Buzz of BIO? Companies from around the world enter for the chance to win free registration and a company presentation in the BIO Business Forum. Who won? Deuteria Pharmaceuticals, Inc., a company that is pioneering ‘Deuterium-Enabled Chiral Switching’ (DECS) to improve the profile of drugs that interconvert between enantiomers both in vitro and in vivo. Stabilizing the preferred isomer improves the product Read More >
Recent Developments in Patentability: Prometheus and Myriad
By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at the 2012 BIO International Convention was a very lively panel discussion on two cases that have set the life science industry on edge. The discussion presented an appropriate diversity of views as experts struggle with how broadly these cases should be interpreted. Briefly, the unanimous decision by the Supreme Court overtuning a decision upholding the Prometheus patents by the Court Read More >
